neostigmine has been researched along with Disease, Pulmonary in 5 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The incidence of postoperative nausea and vomiting (PONV) in PACU was higher in neostigmine-reversed than sugammadex-reversed patients (21." | 5.40 | Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade: sugammadex, neostigmine or no reversal. ( De Mel, A; Falke, L; Gillies, E; Greenaway, M; Johnston, F; Ledowski, T; Phillips, M; Tiong, WS, 2014) |
| "Inappropriate dosing of neostigmine for antagonism of neuromuscular blockade has been associated with postoperative pulmonary complications." | 3.88 | Implementation of a new strategy to improve the peri-operative management of neuromuscular blockade and its effects on postoperative pulmonary complications. ( Agarwala, AV; Chitilian, HV; Doney, AB; Eikermann, M; Houle, TT; Ng, PY; Ramachandran, SK; Rudolph, MI; Timm, FP, 2018) |
| "Sugammadex decreased residual neuromuscular block (10% vs 49%; OR=0." | 2.94 | Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery. ( Aziz, MF; Higgins, JR; Tekkali, P; Togioka, BM; Treggiari, MM; Yanez, D, 2020) |
| "The incidence of postoperative nausea and vomiting (PONV) in PACU was higher in neostigmine-reversed than sugammadex-reversed patients (21." | 1.40 | Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade: sugammadex, neostigmine or no reversal. ( De Mel, A; Falke, L; Gillies, E; Greenaway, M; Johnston, F; Ledowski, T; Phillips, M; Tiong, WS, 2014) |
| "A man with ocular myasthenia gravis had rapidly progressing pulmonary hemorrhage, acute renal failure, arthralgias, and palpable purpura." | 1.26 | Immune complex disease with fatal pulmonary hemorrhage: its occurrence in a patient with myasthenia gravis. ( Collins, AB; Dickersin, GR; Kiprov, D; Kradin, L; Kradin, RL; Mark, EJ, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Togioka, BM | 1 |
| Yanez, D | 1 |
| Aziz, MF | 1 |
| Higgins, JR | 1 |
| Tekkali, P | 1 |
| Treggiari, MM | 1 |
| Rudolph, MI | 1 |
| Chitilian, HV | 1 |
| Ng, PY | 1 |
| Timm, FP | 1 |
| Agarwala, AV | 1 |
| Doney, AB | 1 |
| Ramachandran, SK | 1 |
| Houle, TT | 1 |
| Eikermann, M | 1 |
| Ledowski, T | 1 |
| Falke, L | 1 |
| Johnston, F | 1 |
| Gillies, E | 1 |
| Greenaway, M | 1 |
| De Mel, A | 1 |
| Tiong, WS | 1 |
| Phillips, M | 1 |
| Kradin, RL | 1 |
| Kiprov, D | 1 |
| Dickersin, GR | 1 |
| Collins, AB | 1 |
| Kradin, L | 1 |
| Mark, EJ | 1 |
| Borisko, AS | 1 |
| Chernobrovyĭ, NP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications in Patients 70 Years or Older and Scheduled for 3 Hour or Longer Surgery-A Randomized Controlled Trial[NCT02861131] | Phase 4 | 200 participants (Actual) | Interventional | 2017-01-24 | Completed | ||
| Validation of the REPS Prediction Tool to Improve Quality of Perioperative Care[NCT03585400] | 101,510 participants (Actual) | Observational | 2018-06-29 | Completed | |||
| Importance of Understanding Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal Agents[NCT03585348] | 265,537 participants (Actual) | Observational | 2018-06-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Defined as the number of days between hospital admission and discharge (NCT02861131)
Timeframe: Length of hospitalization, an average of 1 week
| Intervention | days (Mean) |
|---|---|
| Sugammadex | 4.0 |
| Neostigmine | 4.5 |
pneumonia, unplanned re-intubation for any reason other than a return trip to the operating room, and ventilator times greater than 48 hours - excluding operating room time (NCT02861131)
Timeframe: Length of hospitalization, an average of 1 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Sugammadex | 4 |
| Neostigmine | 2 |
A composite outcome which includes any of the following: postoperative pneumonia, aspiration pneumonitis, atelectasis, pneumothorax, desaturation/hypoxemia, upper airway obstruction, or acute respiratory insufficiency (NCT02861131)
Timeframe: Length of hospitalization, an average of 1 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Sugammadex | 33 |
| Neostigmine | 40 |
The proportion of patients that require hospital readmission for any cause within 30 days of hospital discharge (NCT02861131)
Timeframe: Length of hospitalization plus 30 days post-discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Sugammadex | 5 |
| Neostigmine | 15 |
Residual neuromuscular blockade will be defined as a train-of-four ratio < 0.9 taken within 5 minutes of subject arrival in the PACU (NCT02861131)
Timeframe: 1 day
| Intervention | Participants (Count of Participants) |
|---|---|
| Sugammadex | 9 |
| Neostigmine | 46 |
Defined as duration of time required to attain pain control and stable respiratory, haemodynamic, and neurological status (NCT02861131)
Timeframe: 1 day
| Intervention | minutes (Mean) |
|---|---|
| Sugammadex | 97.3 |
| Neostigmine | 110.0 |
1 trial available for neostigmine and Disease, Pulmonary
| Article | Year |
|---|---|
Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Delayed Emergence from Anesthesia; Double-Blind | 2020 |
4 other studies available for neostigmine and Disease, Pulmonary
| Article | Year |
|---|---|
Implementation of a new strategy to improve the peri-operative management of neuromuscular blockade and its effects on postoperative pulmonary complications.
Topics: Adult; Aged; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Hospital Costs; Hu | 2018 |
Implementation of a new strategy to improve the peri-operative management of neuromuscular blockade and its effects on postoperative pulmonary complications.
Topics: Adult; Aged; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Hospital Costs; Hu | 2018 |
Implementation of a new strategy to improve the peri-operative management of neuromuscular blockade and its effects on postoperative pulmonary complications.
Topics: Adult; Aged; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Hospital Costs; Hu | 2018 |
Implementation of a new strategy to improve the peri-operative management of neuromuscular blockade and its effects on postoperative pulmonary complications.
Topics: Adult; Aged; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Hospital Costs; Hu | 2018 |
Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade: sugammadex, neostigmine or no reversal.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Female; gamma-Cyclodextrins; Humans; Lung Disease | 2014 |
Immune complex disease with fatal pulmonary hemorrhage: its occurrence in a patient with myasthenia gravis.
Topics: Adrenal Cortex Hormones; Choroid Plexus; Eye Diseases; Fluorescent Antibody Technique; Hemorrhage; H | 1981 |
[Decurarization with calcium pantothenate after operations on pulmonary patients with bronchial asthma].
Topics: Adult; Asthma; Atropine; Calcium; Drug Therapy, Combination; Electrocardiography; Female; Halothane; | 1974 |